|
CH535201A
(de)
|
1969-12-19 |
1973-03-31 |
Bristol Myers Co |
Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
|
|
JP4694207B2
(ja)
|
2002-07-05 |
2011-06-08 |
コルジウム ファーマシューティカル， インコーポレイテッド |
オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
|
|
WO2007111880A2
(en)
|
2006-03-22 |
2007-10-04 |
Mount Sinai School Of Medicine |
Intranasal administration of ketamine to treat depression
|
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
AU2008286914B2
(en)
|
2007-08-13 |
2014-10-02 |
Ohemo Life Sciences Inc. |
Abuse resistant drugs, method of use and method of making
|
|
NZ589764A
(en)
|
2008-05-09 |
2012-10-26 |
Univ Emory |
NMDA receptor antagonists for the treatment of neuropsychiatric disorders
|
|
US20110038807A1
(en)
|
2009-08-14 |
2011-02-17 |
Demitri Papolos |
Compositions and methods for treating bipolar disorder
|
|
US20120225949A1
(en)
*
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
PE20141906A1
(es)
|
2012-03-12 |
2014-12-05 |
Janssen Pharmaceutica Nv |
Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
|
|
AU2013285988A1
(en)
|
2012-07-06 |
2015-02-12 |
Egalet Ltd. |
Abuse deterrent pharmaceutical compositions for controlled release
|
|
WO2014020155A1
(en)
|
2012-08-02 |
2014-02-06 |
Clinpharm Reform Gmbh |
Oral transmucosal adminstration forms of s-ketamine
|
|
US9468611B2
(en)
|
2012-09-27 |
2016-10-18 |
Relmada Therapeutics, Inc. |
d-Methadone for the treatment of psychiatric symptoms
|
|
WO2014117089A1
(en)
|
2013-01-25 |
2014-07-31 |
Case Western Reserve University |
Compositions and methods for the treatment of pervasive development disorders
|
|
JP6462663B2
(ja)
|
2013-04-12 |
2019-01-30 |
アイカーン スクール オブ メディシン アット マウント シナイ |
心的外傷後ストレス障害を処置するための方法
|
|
US9913803B2
(en)
|
2013-08-26 |
2018-03-13 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
WO2015051259A1
(en)
|
2013-10-04 |
2015-04-09 |
Impax Laboratories, Inc. |
Pharmaceutical compositions and methods of use
|
|
EA032013B1
(ru)
|
2013-10-31 |
2019-03-29 |
Сайма Лэбс Инк. |
Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением
|
|
DK3272338T3
(da)
|
2014-04-17 |
2020-11-02 |
Develco Pharma Schweiz Ag |
Oral doseringsform for ketamin
|
|
CN107208133A
(zh)
|
2014-09-15 |
2017-09-26 |
詹森药业有限公司 |
用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
|
|
AU2015343083B2
(en)
|
2014-11-04 |
2020-07-23 |
Acadia Pharmaceuticals Inc. |
Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
|
|
JP6696994B2
(ja)
|
2014-12-08 |
2020-05-20 |
クレシオ・バイオサイエンシズ・リミテッド |
即放性乱用抑止性顆粒剤形
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
WO2017041112A1
(en)
|
2015-09-04 |
2017-03-09 |
Cyprus Therapeutics, Inc. |
Ketamine and cytochrome p 450 inhibitor combinations
|
|
EP3377050A4
(en)
|
2015-11-17 |
2019-11-20 |
The Trustees of Columbia University in the City of New York |
PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
|
|
US20190240184A1
(en)
|
2016-10-27 |
2019-08-08 |
National University Corporation Chiba University |
Pharmaceutical applications for (s)-norketamine and salts thereof
|
|
ES2991544T3
(es)
|
2016-11-30 |
2024-12-04 |
Wolfson Philip E |
Ketamina para el tratamiento de síntomas relacionados con la menstruación
|
|
EP3641742B1
(en)
|
2017-06-23 |
2026-03-25 |
Ketabon GmbH |
Hydroxynorketamine for the use in the treatment of depression
|
|
MX2020003546A
(es)
*
|
2017-10-10 |
2020-08-03 |
Douglas Pharmaceuticals Ltd |
Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
|
|
MX2020006650A
(es)
|
2017-12-22 |
2020-11-06 |
Janssen Pharmaceuticals Inc |
Esketamina para el tratamiento de la depresión.
|
|
JP2021529732A
(ja)
|
2018-06-27 |
2021-11-04 |
クレキシオ バイオサイエンシーズ エルティーディー． |
大うつ病性障害の処置方法
|
|
KR20210074275A
(ko)
|
2018-10-05 |
2021-06-21 |
클렉시오 바이오사이언시스 리미티드 |
주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
|
|
EP3923920A4
(en)
|
2019-08-05 |
2022-11-23 |
The Ketamine Research Foundation |
KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
WO2021137147A1
(en)
|
2019-12-30 |
2021-07-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|